Michael Steele

Michael Steele

Company: Biocartis

Job title: Vice President, Business Development Pharma Partnering


Clinical need for rapid molecular testing in lung cancer patient management 3:00 pm

• Eighteen per cent (18%) of stage 4 NSCLC patients with non-squamous, NSCLC histology are at risk of rapid clinical deterioration and ¾ of these have a performance status 0, 1 or 2 at first MDT discussion. • Turnaround times for reporting somatic mutations in EGFR could be improved by using rapid, automated PCR-based testing…Read more

day: day 2 - pm -yellow

© Copyright 2023 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Eastcastle House, 27/28 Eastcastle Street, London, W1W 8DH.